Topic: glioblastoma multiforme (GBM)

purple brain

15. Toca 511/Toca FC

After AbbVie’s Depatux-M and Bristol-Myers Squibb’s Opdivo failed to make the grade in brain cancer, Tocagen was left as one of the last companies with a late-stage program in the cancer, but in September, it revealed that its Toca 511/Toca FC gene therapy was also a bust.

6. Opdivo

2019 was something of an annus horribilis when it came to trying to find new therapies for aggressive brain cancer glioblastoma multiforme, and one of the biggest disappointments came from the failure of an immuno-oncology approach to the disease.

1. Depatux-M

High-grade gliomas are one of the toughest tumors to treat, and the first entrant on our alphabetical list—AbbVie’s antibody-drug conjugate Depatux-M—is one of at least three drugs that failed to hit the mark in this highly aggressive form of brain cancer in 2019.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.